Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.

INTRODUCTION Accumulating evidence suggest that drug-induced QT prolongation per se poorly predicts repolarisation-related proarrhythmia liability. We examined whether beat-by-beat variability of the QT interval may be a complementary proarrhythmia marker to QT prolongation. METHODS Anaesthetised rabbits sensitized towards developing torsades de pointes (TdP) were infused for 30 min maximum with explorative antiarrhythmic compounds characterised as mixed ion channel blockers. Based on the outcome in this model the compounds were classified as having a low (TdPlow; n=5), intermediate (TdPintermediate; n=7) or high (TdPhigh; n=10) proarrhythmic potential. Dofetilide (n=4) was included as a representative of a selective IKr-blocking antiarrhythmic with known high proarrhythmic potential. QT interval prolongation and beat-by-beat QT variability (quantified as the short-term variability, STV) were continuously assessed during the infusion or up to the point where ventricular proarrhythmias were induced. RESULTS All compounds significantly prolonged the QT interval. For TdPlow and TdPhigh compounds the QT interval maximally increased from 169 ± 14 to 225 ± 28 ms (p<0.05) and from 186 ± 21 to 268 ± 42 ms (p<0.01), respectively. Likewise, in the dofetilide-infused rabbits the QT interval maximally increased from 177 ± 11 to 243 ± 25 ms (p<0.01). In contrast, whereas the STV in rabbits administered the TdPhigh compounds or dofetilide significantly increased prior to proarrhythmia induction (from 1.6 ± 0.4 to 10.5 ± 5.6 ms and from 1.6 ± 0.5 to 5.9 ± 1.8 ms, p<0.01) it remained unaltered in the TdPlow group (1.3 ± 0.6 to 2.2 ± 0.9 ms). In the TdPintermediate group, rabbits experiencing TdP had a similar maximal QT prolongation as the non-susceptible rabbits whereas the change in the STV was significantly different (from 0.9 ± 0.5 to 8.7 ± 7.3 ms vs 0.8 ± 0.3 to 2.5 ± 1.1 ms). DISCUSSION It is concluded from the present series of experiments in a sensitive rabbit model of TdP that increased beat-by-beat QT interval variability precedes drug-induced TdP. In addition, assessment of this potential proarrhythmia marker may be useful in discriminating highly proarrhythmic compounds from compounds with a low proarrhythmic potential.

[1]  P. Kowey,et al.  Assessment of the Proarrhythmic Potential of the Novel Antiarrhythmic Agent AZD7009 and Dofetilide in Experimental Models of Torsades De Pointes , 2005, Journal of cardiovascular electrophysiology.

[2]  N. Abi-Gerges,et al.  The combined ion channel blocker AZD1305 attenuates late Na current and IKr-induced action potential prolongation and repolarization instability. , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[3]  L. Carlsson.  The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes. , 2008, Pharmacology & therapeutics.

[4]  J. Dempster,et al.  Potentiation of E‐4031‐induced torsade de pointes by HMR1556 or ATX‐II is not predicted by action potential short‐term variability or triangulation , 2007, British journal of pharmacology.

[5]  T. Garyantes,et al.  Development and Evaluation of High Throughput Functional Assay Methods for hERG Potassium Channel , 2001, Journal of biomolecular screening.

[6]  Martin Hinterseer,et al.  Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study. , 2007, European heart journal.

[7]  Leif Carlsson,et al.  Assessment of the Ion Channel-blocking Profile of the Novel Combined Ion Channel Blocker AZD1305 and Its Proarrhythmic Potential Versus Dofetilide in the Methoxamine-sensitized Rabbit In Vivo , 2009, Journal of cardiovascular pharmacology.

[8]  J. Brachmann,et al.  Early Electrocardiographic Signs of Drug‐Induced Torsades de Pointes , 1998 .

[9]  R. Shah,et al.  Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. , 2005, Heart rhythm.

[10]  L. Carlsson,et al.  QTU‐Prolongation and Torsades de Pointes Induced by Putative Class III Antiarrhythmic Agents in the Rabbit: Etiology and Interventions , 1990, Journal of cardiovascular pharmacology.

[11]  Frida Persson,et al.  Blocking Characteristics of hERG, hNav1.5, and hKvLQT1/hminK after Administration of the Novel Anti‐Arrhythmic Compound AZD7009 , 2005, Journal of cardiovascular electrophysiology.

[12]  G. Hanton,et al.  Temporal variability of QT interval and changes in T wave morphology in dogs as markers of the clinical risk of drug-induced proarrhythmia. , 2008, Journal of pharmacological and toxicological methods.

[13]  Milan Stengl,et al.  Increased Short-Term Variability of Repolarization Predicts d-Sotalol–Induced Torsades de Pointes in Dogs , 2004, Circulation.

[14]  L. Carlsson,et al.  Potassium and calcium current blocking properties of the novel antiarrhythmic agent H 345/52: implications for proarrhythmic potential. , 2001, Cardiovascular research.

[15]  P. Hoffmann,et al.  Blinded Test in Isolated Female Rabbit Heart Reliably Identifies Action Potential Duration Prolongation and Proarrhythmic Drugs: Importance of Triangulation, Reverse Use Dependence, and Instability , 2003, Journal of cardiovascular pharmacology.

[16]  R. Ruffolo,et al.  Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. , 1996, The Journal of pharmacology and experimental therapeutics.

[17]  S. Snyder,et al.  (-)-[3H] desmethoxyverapamil labels multiple calcium channel modulator receptors in brain and skeletal muscle membranes: differentiation by temperature and dihydropyridines. , 1986, The Journal of pharmacology and experimental therapeutics.

[18]  Rita R. Patel,et al.  A High-Throughput HERG Potassium Channel Function Assay: An Old Assay with a New Look , 2002, Drug development and industrial pharmacy.

[19]  D. Fedida,et al.  RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. , 2006, Cardiovascular research.

[20]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[21]  G. B. Brown,et al.  3H-batrachotoxinin-A benzoate binding to voltage-sensitive sodium channels: inhibition by the channel blockers tetrodotoxin and saxitoxin , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[22]  F. Persson.  Mechanism of Action of the Antiarrhythmic Agent AZD7009 , 2007 .

[23]  P. Makra,et al.  Relevance of anaesthesia for dofetilide‐induced torsades de pointes in α1‐adrenoceptor‐stimulated rabbits , 2008, British journal of pharmacology.

[24]  M. Rosenqvist,et al.  Rapid Conversion of Persistent Atrial Fibrillation to Sinus Rhythm by Intravenous AZD7009 , 2009, Journal of clinical pharmacology.

[25]  G Duker,et al.  Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? , 1997, The Journal of pharmacology and experimental therapeutics.

[26]  G. Duker,et al.  Instability and Triangulation of the Action Potential Predict Serious Proarrhythmia, but Action Potential Duration Prolongation Is Antiarrhythmic , 2001, Circulation.

[27]  L. Belardinelli,et al.  Antitorsadogenic Effects of (±)-N-(2,6-Dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (Ranolazine) in Anesthetized Rabbits , 2008, Journal of Pharmacology and Experimental Therapeutics.

[28]  P. Volders,et al.  Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias. , 2006, Pharmacology & therapeutics.

[29]  L. Carlsson,et al.  Attenuation of proarrhythmias related to delayed repolarization by low-dose lidocaine in the anesthetized rabbit. , 1993, The Journal of pharmacology and experimental therapeutics.

[30]  A Varró,et al.  Combined pharmacological block of IKr and IKs increases short‐term QT interval variability and provokes torsades de pointes , 2007, British journal of pharmacology.